Allergic rhinitis: Current options and future perspectives

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 2, 2014, Pages 168-176

  Braido, Fulvio ^a   Arcadipane, Federica ^a   Marugo, Fiorenza ^a   Hayashi, Mituki ^b   Pawankar, Ruby ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

allergic rhinitis; drugs safety; efficacy; treatment

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ALLERGIC RHINITIS; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW;

ANIMALS; ANTI-ALLERGIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84896733390     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000043     Document Type: Review

References (98)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (5 Suppl):S147-S334.
2. Durham SR. The inflammatory nature of allergic disease. Clin Exp Allergy 1998; 28 (Suppl 6):20-24.
3. Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62 (Suppl):1-41.
4. Brozek JL, Bousquet J, Baena-Cagnani CE, et al., Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466-476.
5. Shaaban R, Zureik M, Soussan D, et al. Allergic rhinitis and onset of bronchial hyperresponsiveness: a population-based study. Am J Respir Crit Care Med 2007; 176:659-666.
6. Rochat MK, Illi S, Ege MJ, et al. Allergic rhinitis as a predictor for wheezing onset in school-aged children. J Allergy Clin Immunol 2010; 126:1170-1175.
7. Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001; 1:7-13.
8. Smart BA. Is rhinosinusitis a cause of asthma? Clin Rev Allergy Immunol 2006; 30:153-164.
9. Durham SR. Effect of intranasal corticosteroid treatment on asthma in children and adults. Allergy 1999; 54:124-131.
10. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250-256.
11. Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 micrograms) reduce nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98:274-282.
12. Watson WT, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91:97-101.
13. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized controlled trial. J Allergy Clin Immunol 1995; 95:923-932.
14. Pasquali M, Baiardini I, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006; 36:1161-1167.
15. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial. Clin Exp Allergy 2005; 35:723-727.
16. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147-S334.
17. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011; 106:S12-S16.
18. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:116-134.
19. Broide DH. Allergic rhinitis: pathophysiology. Allergy Asthma Proc 2010; 31:370-374.
20. Bousquet J, Bodez T, Gehano P, et al. Implementation of guidelines for allergic rhinitis in specialist practices: a randomized pragmatic controlled trial. Int Arch Allergy Immunol 2009; 150:75-82.
21. Siracusa A, Folletti I, Moscato G. Non-IgE-mediated and irritant-induced work-related rhinitis. Curr Opin Allergy Clin Immunol 2013; 13:159-166.
22. Simons FE, Simons KJ. Histamine and H 1 antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139-1150.
23. Zhang L, Cheng L, Hong J. The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacology 2013; 92:14-25.
24. Carr WW. New therapeutic options for allergic rhinitis: back to the future with intranasal corticosteroid aerosols. Am J Rhinol Allergy 2013; 27:309-313.
25. Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2011; 32:413-418.
26. LaForce C, Journeay GE, Miller SD, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study. Ann Allergy Asthma Immunol 2013; 111:45-50.
27. Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000; 79:690.
28. Kushnir NM. The role of decongestants, cromolyn, guafenesin, saline washes, capsaicin, leukotriene antagonists, and other treatments on rhinitis. Immunol Allergy Clin North Am 2011; 31:601-617.
29. Lee C, Corren J. Review of azelastine nasal spray in the treatment of allergic and nonallergic rhinitis. Expert Opin Pharmacother 2007; 8:701-709.
30. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet 2011; 378:2112-2122.
31. Gotoh M, Okubo K, Hashiguchi K, et al. Noninvasivebiological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis. Allergy Asthma Proc 2012; 33:459-466.
32. Braido F, Riccio AM, Rogkakou A, et al. Montelukast effects on inflammation in allergic rhinitis: a double blind placebo controlled pilot study. Eur Ann Allergy Clin Immunol 2012; 44:48-53.
33. Hatzler L, Panetta V, Lau S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol 2012; 130:894-901.
34. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immu-notherapy. Allergy 2011; 66:725-732.
35. Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006; 18:738-744.
36. Durham SR, Walker SM, Varga EV, et al. Long-term clinical efficacy of grasspollen immunotherapy. N Engl J Med 1999; 341:468-475.
37. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1-S84.
38. Windom HH, Lockey RF. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8:571-576.
39. James LK, Durham SR. Update on mechanisms of allergen injection immu-notherapy. Clin Exp Allergy 2008; 38:1074-1088.
40. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and nonallergic rhinitis. Clin Exp Allergy 2008; 38:19-42.
41. Fan Y, Ma L, Pippins J, et al. Impact of study design on the evaluation of inhaled and intranasal corticosteroids' effect on hypothalamic-pituitary- adre-nal axis function, Part I: general overview of HPA axis study design. J Pharm Sci 2013; 102:3513-3527.
42. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012; 22:1-12.
43. Neffen H, Wingertzahn MA. Ciclesonide, a hypotonic intranasal corticoster-oid. Allergy Asthma Proc 2010; 31:S29-S37.
44. Mohar D, Berger WE, Laforce C, et al. Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Allergy Asthma Proc 2012; 33:19-26.
45. Jacobs RL. Ciclesonide for the treatment of seasonal allergic rhinitis. Expert Rev Clin Immunol 2011; 7:735-741.
46. Berger WE, Mohar DE, LaForce C, et al. A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Am J Rhinol Allergy 2012; 26:302-307.
47. Ahlström-Emanuelsson C, Andersson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy 2004; 34:731-735.
48. Klimek L, Sperl A. Evidence-based treatment options for allergic diseases in otolaryngology: an update. HNO 2013; 61:525-538.
49. Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opin Pharmacother 2013; 14:2101-2113.
50. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013; 161:369-377.
51. Wolthers OD. New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. Recent Pat Inflamm Allergy Drug Discov 2013; 7:223-228.
52. Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012; 33:324-332.
53. Ciprandi G. Clinical utility and patient adherence in the use of ebastine for allergic rhinitis. Patient Preference Adherence 2010; 4:389-395.
54. Metz M, Maurer M. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Rev Clin Immunol 2011; 7:15-20.
55. Siebenhaar F, Fö rtsch A, Krause K, et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013; 68:949-952.
56. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, place bo-controlled studies with meta-analysis. Curr Med Res Opin 2013; 29:1539-1551.
57. Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: a randomized, double-blind, placebo-controlled study. Pediatr Allergy Immunol 2013; 24:144-150.
58. Bousquet J, Ansótegui I, Canonica GW, et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28:131-139.
59. Carter NJ. Bilastine in allergic rhinitis and urticaria. Drugs 2012; 72:1257-1269.
60. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci 2012; 16:1999-2005.
61. Bachert C, Kuna P, Sanquer F, et al., Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64:158-165.
62. Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6:371-384.
63. Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res 2011; 60:1107-1112.
64. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010; 59:391-398.
65. Kuna P, Bachert C, Nowacki Z, et al., Bilastine International Working Group. Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39:1338-1347.
66. Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52:893-903.
67. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 2011; 10:779-793.
68. Lazewska D, Kiec-Kononowicz K. Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed) 2012; 4:967-987.
69. Kiss R, Keseru GM. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat 2012; 22:205-221.
70. Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 2012; 158:84-98.
71. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108:530-536.
72. Erin EM, Leaker BR, Zacharasiewicz A, et al. Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin Exp Allergy 2006; 36:458-464.
73. Rimmer J, Peake HL, Santos CM. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2007; 37:8-14.
74. John M, Eisenberg Center for Clinical Decisions and Communications Science. Subcutaneous and Sublingual Immunotherapy To Treat Allergic Rhinitis/Rhinoconjunctivitis and Asthma. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007; www.ncbi.nlm.nih.gov/books/NBK 158932. [Accessed on 22Aug 2013]
75. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127:8-15.
76. Senti G, Prinz Vavricka BM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008; 105:17908-17912.
77. Senti G, von Moos S, Kündig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011; 66:798-809.
78. Creticos PS, Eiden JJ, Broide DH, et al. Immunotherapy with immunostimu-latory oligonucleotides linked to purified ragweed Amb a1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J Allergy Clin Immunol 2002; 109:743-744.
79. Drachenber KJ, Wheeler A, Stubner P, Horak F. A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant MPL reduces allergy symptoms after only four preseasonal injections. Allergy 2001; 56: 498-505.
80. Greiff L, Cervin A, Ahlströ m-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res 2012; 13:53.
81. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122:951-960.
82. Tan Y, Li Y, Liu D, Zhong L. Suplatast tosilate ameliorates airway hyperreac-tivity and inflammation through inhibition of the GATA-3/IL-5 signaling pathway in asthmatic rats. Mol Med Rep 2013; 8:161-167.
83. Alenmyr L, Greiff L, Andersson M, et al. Effect of mucosal TRPV1 inhibition in allergic rhinitis. Basic Clin Pharmacol Toxicol 2012; 110:264-268.
84. Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther 2013; 51:576-584.
85. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128:597-602.
86. Casale TB. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol 2001; 108:S84-S88.
87. Grundmann SA, Hemfort PB, Luger TA, et al. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 2008; 121:257-258.
88. Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 2012; 67:1572-1579.
89. Böhm M, Avgitidou G, El Hassan E, Mösges R. Liposomes: a new nonphar-macological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol 2012; 269:495-502.
90. Food and Agriculture Organization World Health Organization (FAO/WHO) Report of Joint FAO/WHO expert consultation on evaluation of health and nutri tional properties of probiotics in food including powder milk with live lactic acid bacteria. FAO/WHO Report no. 10-1-2001. WHO INT; Córdoba, Argentina
91. Kallomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo controlled trial. Lancet 2001; 357:1076-1079.
92. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for the treatment of eczema: a systematic review. Clin Exp Allergy 2009; 39:1117-1127.
93. Lue KH, Sun HL, Lu KH, et al. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. Int J Pediatr Otorhinolaryngol 2012; 76:994-1001.
94. Singh A, Hacini-Rachinel F, Gosoniu ML, et al. Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. Eur J Clin Nutr 2013; 67:161-167.
95. Das RR, Naik SS, Singh M. Probiotics as additives on therapy in allergic airway diseases: a systematic review of benefits and risks. Biomed Res Int 2013; 2013:231979.
96. Cuppari C, Salpietro A, Grasso L, et al. HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment. The Child 2012; 2:8.
97. Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the allergic rhinitis and its impact on asthma guideline 2008 update. Allergy 2008; 63:38-46.
98. Bousquet J, Bachert C, Canonica GW, et al., Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009; 124:428-433.